Syntab Therapeutics

Syntab Therapeutics is a private, preclinical-stage biotech pioneering a new approach in immuno-oncology with its proprietary Immune System Engager (ISEr) platform. These small, chemically derived molecules are designed to reprogram the innate immune system to specifically recognize and destroy cancer cells, with a lead program targeting triple-negative breast cancer. The company claims advantages in tissue penetration, manufacturing simplicity, and development speed compared to biologic therapies. Syntab is building a pipeline focused on hard-to-treat cancers and metastatic disease.

Immune System Engager (ISEr) platform: small (5-10 kD), chemically synthesized, modular molecules that combine cancer-cell-targeting binders with innate immune system activators.

Syntab competes in the crowded immuno-oncology space against large pharma and biotechs developing antibodies, cell therapies, and other modalities. Its specific niche—small molecule innate immune engagers—faces competition from other companies exploring similar pathways (e.g., CD47, STING agonists) but its fully chemical, multi-specific design is a differentiating approach.